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Immunohistochemical Detection of Pulmonary
Cytochrome P4501A and Metabolic Activities
Associated with P4501A1 and P4501A2
Isozymes in Lung Cancer Patients
by Sisko Anttila,1 Harri Vainio,2 Eino Hietanen,3 Anne-
Marie Camus,4 Christian Malaveille,2 Gisele Brun,2
Kirsti Husgafvel-Pursiainen,1 Lasse Heikkila,n Antti
Karjalainen,' and Helmut Bartsch2
The main polycyclic aromatic hydrocarbon-inducible cytochrome P450 was studied in lung tissue from 57
lung cancer patients by immunohistochemistry, using a monoclonal antibody (1-7-1) that recognizes P450IA1
and P450IA2 isozymes. The intensity of immunostaining was compared with the pulmonary activity of a
P450IA1-dependent enzyme, aryl hydrocarbon hydroxylase (AHH), and with P450IA2-related metabolic
activity estimated from the ratio of caffeine metabolites in urine. Immunostaining was not observed in
peripheral lungtissue ofnonsmokers orex-smokersbutwas seen inthebronchiolarandalveolarepitheliumof
all patients who were smokers and had a peripheral carcinoma (16/16) and of60% (10/17) ofthose who had a
bronchial carcinoma. AHH activity was positively related to the intensity ofimmunostaining, and an almost
2-fold increase due to smoking was detected in the ratios ofcaffeine metabolites. These results demonstrate
that tobacco smoke induces P450IA1 in the lung and probably P450IA2 in the liver, and suggest a role for
certain metabolic phenotypes ofP450IA1 in peripheral pulmonary carcinoma.
Introduction
Tobacco smoke contains several classes ofcarcinogens;
ofthesepolycyclic hydrocarbons and aromatic amines may
be preferentially metabolized by members of the P450
superfamily including P450IA1 and P450IA2 enzymes.
P450IA1 is presumed to be important in pulmonary car-
cinogenesis, since itis involved in the biotransformation of
polycyclic hydrocarbons to yield reactive intermediates
that can bind to DNA (1-3). P450IA2 is mainly a hepatic
enzymethatcatalyzestheinitialactivationstepofprimary
arylamines and is also involved in caffeine biotransforma-
tion (4). P450IA1 mRNA (CYPlAl gene) is expressed in
human lung (5), but the role ofpulmonary P450IA2 in the
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metabolism of aromatic amines in tobacco smoke is
regarded as negligible.
We have used immunohistochemistry previously to
examine the presence and location of pulmonary cyto-
chrome P450IA1 and P45IA2 induced bytobacco smoking
in lung cancer patients. As the monoclonal antibody used
recognizes both P450IA1 and P450IA2, we use the term
P450IA enzymes. The enzyme was found in the alveolar
and bronchiolar epithelial cells of all patients who had a
peripheral cancer, and in about half of those who had a
bronchial cancer (6). The aim ofthis studywas to confirm
with a larger number of patients that the inducibility of
P450IA differs between patients with different lung can-
cer types. The activity of a P450IAl-dependent enzyme,
aryl hydrocarbonhydroxylase (AHH), determined in lung
tissue homogenates, and P450IA2-related metabolic
activity, which was estimated from the ratio of caffeine
metabolites in urine from the same patients, were related
to the immunohistochemical findings in the lung.
Patients and Methods
Forty-nine male and eight female lung cancer patients
were interviewed prior to lung surgery about their smok-ANTTILA ET AL.
ing habits, occupational history and use of alcohol and
drugs. The age ofthe patients ranged from 35 to 78 years
(mean, 60 years). Four ofthemwere nonsmokers, 35 were
currentsmokers, and19wereex-smokersamongwhomthe
time since stopping smoking ranged from 2 months to 48
years. Twenty-four-hour urine samples were collected
from all patients at the hospital.
For immunohistochemistry and enzyme assays, fresh
lung tissue was taken from surgical lobectomy or pulmec-
tomy specimens and kept at -70°C until analyzed. The
remaining surgical specimens were fixed with 10% for-
malin, and the histological samples were processed con-
ventionallyforlight microscopy. The histological type and
the point oforigin ofthe tumors, whetherin cartilaginous
bronchi or in more peripheral airways, were examined. In
three cases, the site of origin could not be determined
because ofthe large size ofthe tumor. Thirty-one tumors
were bronchial carcinomas: 25 squamous-cell carcinomas,
4 small-cell carcinomas, 1 large-cell carcinoma, and 1 ade-
nocarcinoma; and 23 were peripheral: 18 adenocarcino-
mas,4squamous-cell carcinomas, and1large-cellcarcinoma.
For immunohistochemistry, frozen sections were
stained with a monoclonal antibody (Mab 1-7-1) raised
against a methyl-cholanthrene-inducible rat cytochrome
P450 isozyme (provided by H. Gelboin and S. S. Park,
National Cancer Institute, Bethesda, MD) using an
avidin-biotin-peroxidase method (6,7). Immunostaining of
peripheral lungtissue was classified into three grades: no
staining, positive, and strongly positive (ifalarge number
of both bronchiolar and alveolar epithelial cells were
stained).
Tb measure AHH activity, the lung samples were homog-
enized and the microsomal fraction was separated. AHH
activity was determined by the fluorimetric method of
Nebert and Gelboin (8), which has a detection limit of0.05
pmole 3-hydroxybenzo[a]pyrene [min]-'[mg]-1 protein.
A high-performance liquid chromatographic method
was used to quantify the urinary levels ofcaffeine (137X)
and its metabolites, i.e., 1,7-dimethylxanthine (17X),
1-methylxanthine (1X), 1-methyluric acid (1U), 1,7-dimeth-
yluric acid (17U) and 5-acetylamino-6-amino-3-methyl-
uracil (AAMU), as described previously (9,10). The ratio
17X/137X has been measured in 30 patients and that of
AAMU + 1U + 1X/17Uin37patientsto date.Theseratios
reflect P450IA2-dependent metabolic activities, mostly in
the liver.
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FIGURE L Immunostainingoffrozensections fromperipherallungtissueshowscytochromeP450IAinbronchiolar(A)andalveolarepithelium(B). In
a longitudinal section of a bronchiolus, strongly immunopositive columnar ciliated epithelial cells can be seen (arrowheads, A). At the center of B,
immunopositive alveolar type I epithelial cells line alveolar spaces; some positive type II cells are also visible (arrowheads, B). Immunoperoxidase,
hematoxylin counterstain. Bar = 40 pum.
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Results and Discussion
Detection of pulmonary cytochrome P450IA by immu-
nohistochemical stainingrequiresinductionbysmoke con-
stituents, as this cytochrome cannot be detected in lung
tissue from nonsmokers and ex-smokers (6) and the
activity ofAHH in lung tissue vanishes within 2 months
after stopping smoking (11). Peripheral lung tissue from
smokers showed patchyimmunopositive areas localized in
bronchiolar and in type I and type II alveolar epithelial
cells; in strongly positive cases, they were also found in
vascular endothelium (Fig. 1). AHH activityin lung tissue
homogenate was positively related to the intensity of
immunohistochemical staining in lung tissue from the
same patients (Fig. 2A). The ratios ofcaffeine metabolites
were less clearly associated with P450IAimmunostaining
and smoking: on a plot ofthe 17X/137X caffeine ratios, no
correlation was apparent (not shown), but a 1.8-fold effect
on the AAMU + 1X + 1U/17U ratio due to smoking (p <
0.01) was seenwith some positive trend with the intensity
of immunostaining (Fig. 2B). These results demonstrate
the inducing effect of tobacco smoke on P450IA1 in the
lung and on P450IA2 probably in the liver of smokers
(4,12). Further molecular analyses are required to deter-
mine whether CYP1A2 and other CYPs are expressed in
the lungs of smokers.
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Peripheral lung tissue was P450IA-immunopositive in
all patients who smoked and had aperipheral lung cancer
(16/16) but in only about 60% (10/17) of those who had a
bronchialcancer.Thisresultisconsistentwiththefindings
in the first25 patients published earlier. We also observed
muchweakerP450IAimmunostaininginbronchialthanin
peripheral airway epithelium in both cancer types (6).
Metabolic transformation of polycyclic hydrocarbons by
P450IA thus seems to take place in the same part ofthe
airways and in the same cell types as those in which
peripheral carcinomas arise. Our finding of inducible
cytochrome P450IA in all patients with peripheral pul-
monary carcinoma and the location of this cytochrome
suggest that these patients may be especially prone to
cancer induced by tobacco smoking and the risk is
increased in certain metabolic phenotypes.
This manuscript was presented as a poster at the Conference on
Biomonitoring and Susceptibility Markers in Human Cancer: Applica-
tions in Molecular Epidemiology and Risk Assessment that was held in
Kailua-Kona, Hawaii, 26 October-1 November 1991.
Thisstudywas supportedbytheThrkuUniversity Foundation,Thrku,
the Juho Vainio Foundation, the Finnish Work Environment Fund and
the Finnish Foundation for Cancer Research, Helsinki, Finland. We
thank Sirkka-Liisa Sarpolaand TuulaStjernvall fortechnical assistance
in collectingsamples, inimmunohistochemistry andinthepreparation of
the photomicrographs.
AUX/17U
0
0
U
NS
0
1
0
S
U
.
0
0
U
so
_ ~+ .++
P4501A immunostaining
A
_ +~-I ++
P4501A immunostaining
B
FIGURE 2. Immunostaining ofperipheral lungtissuecomparedwitharyl hydrocarbon hydroxylase(AHH) activity(pmole [mg]-'[min]-l) in lungtissue
homogenate (A) and with the urinary caffeine metabolite ratio AAMU + 1U + 1X (AUX)/17U (B). In the first column ofboth parts ofthe figure, the
mean values with standard deviations are indicated separately for current smokers (S) and nonsmokers including ex-smokers (NS). (-), no staining;
(+), positive; (+ +), strongly positive.
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